Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Amélie Boichard, Timothy V. Pham, Huwate Yeerna, Aaron Goodman, Pablo Tamayo, Scott Lippman, Garrett M. Frampton, Igor F. Tsigelny & Razelle Kurzrock. (2019) APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. OncoImmunology 8:3.
Read now
Read now
Faezeh Borzooee, Mahdi Asgharpour, Emma Quinlan, Michael D. Grant & Mani Larijani. (2018) Viral subversion of APOBEC3s: Lessons for anti-tumor immunity and tumor immunotherapy. International Reviews of Immunology 37:3, pages 151-164.
Read now
Read now
Articles from other publishers (51)
Hengyuan Miao, Ercan Engin Kuruoğlu & Tao Xu. (2023) Non-homogeneous Poisson and renewal processes as spatial models for cancer mutation. Computational Biology and Chemistry 106, pages 107922.
Crossref
Crossref
Haonan Jiang, Guzhanuer Awuti & Xiaoqing Guo. (2023) Construction of an Immunophenoscore-Related Signature for Evaluating Prognosis and Immunotherapy Sensitivity in Ovarian Cancer. ACS Omega 8:36, pages 33017-33031.
Crossref
Crossref
Hirotaka Miyashita, Razelle Kurzrock, Nicholas J. Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Sean T. Glenn, Jeffrey M. Conroy, Paul DePietro, Eitan Rubin, Jason K. Sicklick & Shumei Kato. (2023) T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy. npj Genomic Medicine 8:1.
Crossref
Crossref
Li-Zhi Luo, Sheng Li, Chen Wei, Jiao Ma, Li-Mei Qian, Yan-Xing Chen, Shi-Xiang Wang & Qi Zhao. (2023) Unveiling the interplay between mutational signatures and tumor microenvironment: a pan-cancer analysis. Frontiers in Immunology 14.
Crossref
Crossref
Kelly Butler & A. Rouf Banday. (2023) APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential. Journal of Hematology & Oncology 16:1.
Crossref
Crossref
Zheyun Niu, Dongming Jiang, Jiaying Shen, Wenbin Liu, Xiaojie Tan & Guangwen Cao. (2023) Potential Role of the Fragile Histidine Triad in Cancer Evo-Dev. Cancers 15:4, pages 1144.
Crossref
Crossref
Minji Kwon, Jiwoo Jung, Hee Sun Park, Na Hui Kim, Jiwoo Lee, Jayeon Park, Youjin Kim, Seokwon Shin, Byung Soo Lee, Ye Hwang Cheong, Hyung-Sun Youn, Sung Roul Kim & Sin-Aye Park. (2023) Diesel exhaust particle exposure accelerates oxidative DNA damage and cytotoxicity in normal human bronchial epithelial cells through PD-L1. Environmental Pollution 317, pages 120705.
Crossref
Crossref
Ting Peng, Binghan Liu, Shitong Lin, Canhui Cao, Ping Wu, Wenhua Zhi, Ye Wei, Tian Chu, Lingli Gui & Wencheng Ding. (2022) APOBEC3G expression correlates with unfavorable prognosis and immune infiltration in kidney renal clear cell carcinoma. Heliyon 8:12, pages e12191.
Crossref
Crossref
Tony M. MertzChristopher D. CollinsMadeline DennisMargo CoxonSteven A. Roberts. (2022) APOBEC-Induced Mutagenesis in Cancer. Annual Review of Genetics 56:1, pages 229-252.
Crossref
Crossref
Yoo-Ah Kim, Ermin Hodzic, Bayarbaatar Amgalan, Ariella Saslafsky, Damian Wojtowicz & Teresa M. Przytycka. (2022) Mutational Signatures as Sensors of Environmental Exposures: Analysis of Smoking-Induced Lung Tissue Remodeling. Biomolecules 12:10, pages 1384.
Crossref
Crossref
Shiro Takamatsu, Junzo Hamanishi, J B Brown, Ken Yamaguchi, Koji Yamanoi, Kosuke Murakami, Osamu Gotoh, Seiichi Mori, Masaki Mandai & Noriomi Matsumura. (2022) Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy. Journal for ImmunoTherapy of Cancer 10:7, pages e004831.
Crossref
Crossref
Erik N Bergstrom, Mousumy Kundu, Noura Tbeileh & Ludmil B Alexandrov. (2022) Examining clustered somatic mutations with SigProfilerClusters. Bioinformatics 38:13, pages 3470-3473.
Crossref
Crossref
Yunzhen Qian, Yitao Gong, Xuan Zou, Yu Liu, Yusheng Chen, Ruijie Wang, Zhengjie Dai, Yesiboli Tasiheng, Xuan Lin, Xu Wang, Guopei Luo, Xianjun Yu, He Cheng & Chen Liu. (2022) Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. Oncogenesis 11:1.
Crossref
Crossref
Erik N. Bergstrom, Jens Luebeck, Mia Petljak, Azhar Khandekar, Mark Barnes, Tongwu Zhang, Christopher D. Steele, Nischalan Pillay, Maria Teresa Landi, Vineet Bafna, Paul S. Mischel, Reuben S. Harris & Ludmil B. Alexandrov. (2022) Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. Nature 602:7897, pages 510-517.
Crossref
Crossref
Ren-Hao Chan, Po-Chuan Chen, Yu-Min Yeh, Bo-Wen Lin, Kai-Di Yang, Meng-Ru Shen & Peng-Chan Lin. (2022) The Expression Quantitative Trait Loci in Immune Response Genes Impact the Characteristics and Survival of Colorectal Cancer. Diagnostics 12:2, pages 315.
Crossref
Crossref
Sadaf Qureshi, Nancy Chan, Mridula George, Shridar Ganesan, Deborah Toppmeyer & Coral Omene. (2022) Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker. Biomarker Insights 17, pages 117727192210787.
Crossref
Crossref
Timothy V. Pham, Aaron M. Goodman, Smruthy Sivakumar, Garrett Frampton & Razelle Kurzrock. (2021) Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers. Genome Medicine 13:1.
Crossref
Crossref
Constantinos Roufas, Ilias Georgakopoulos-Soares & Apostolos Zaravinos. (2021) Distinct genomic features across cytolytic subgroups in skin melanoma. Cancer Immunology, Immunotherapy 70:11, pages 3137-3154.
Crossref
Crossref
Gene Koh, Andrea Degasperi, Xueqing Zou, Sophie Momen & Serena Nik-Zainal. (2021) Mutational signatures: emerging concepts, caveats and clinical applications. Nature Reviews Cancer 21:10, pages 619-637.
Crossref
Crossref
Kailiang Zhao, Qiang Zhang, Sheryl A. Flanagan, Xueting Lang, Long Jiang, Leslie A. Parsels, Joshua D. Parsels, Weiping Zou, Theodore S. Lawrence, Rémi Buisson, Michael D. Green & Meredith A. Morgan. (2021) Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner. Molecular Cancer Research 19:9, pages 1571-1582.
Crossref
Crossref
Job van Riet, Harmen J. G. van de Werken, Edwin Cuppen, Ferry A. L. M. Eskens, Margot Tesselaar, Linde M. van Veenendaal, Heinz-Josef Klümpen, Marcus W. Dercksen, Gerlof D. Valk, Martijn P. Lolkema, Stefan Sleijfer & Bianca Mostert. (2021) The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets. Nature Communications 12:1.
Crossref
Crossref
Alfredo Addeo, Alex Friedlaender, Giuseppe L. Banna & Glen J. Weiss. (2021) TMB or not TMB as a biomarker: That is the question. Critical Reviews in Oncology/Hematology 163, pages 103374.
Crossref
Crossref
Denis L. Jardim, Aaron Goodman, Debora de Melo Gagliato & Razelle Kurzrock. (2021) The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell 39:2, pages 154-173.
Crossref
Crossref
Milaid Granadillo Rodríguez, Ben Flath & Linda Chelico. (2020) The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead. Open Biology 10:12.
Crossref
Crossref
Anya Levinson, Alex G. Lee, Henry J. Martell, Marcus R. Breese, Charles Zaloudek, Jessica Van Ziffle, Benjamin Laguna, Stanley G. Leung, M. Dwight Chen, Lee-may Chen, Jacob Pfeil, Nicholas R. Ladwig, Avanthi Tayi Shah, Inge Behroozfard, Arjun Arkal Rao, Sofie R. Salama, E. Alejandro Sweet-Cordero & Elliot Stieglitz. (2020) Complete Response to PD-1 Inhibition in an Adolescent With Relapsed Clear Cell Adenocarcinoma of the Cervix Predicted by Neoepitope Burden and APOBEC Signature. JCO Precision Oncology:4, pages 1321-1332.
Crossref
Crossref
Timothy V. Pham, Amélie Boichard, Aaron Goodman, Paul Riviere, Huwate Yeerna, Pablo Tamayo & Razelle Kurzrock. (2020) Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Molecular Oncology 14:8, pages 1680-1694.
Crossref
Crossref
ChangYin Feng, YingYing Zhang, JianPing Huang, QiaoLing Zheng, YingHong Yang & BenHua Xu. (2020) The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma. Applied Immunohistochemistry & Molecular Morphology Publish Ahead of Print.
Crossref
Crossref
Shridar Ganesan & Janice Mehnert. (2020) Biomarkers for Response to Immune Checkpoint Blockade. Annual Review of Cancer Biology 4:1, pages 331-351.
Crossref
Crossref
R. Barroso-Sousa, E. Jain, O. Cohen, D. Kim, J. Buendia-Buendia, E. Winer, N. Lin, S.M. Tolaney & N. Wagle. (2020) Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Annals of Oncology 31:3, pages 387-394.
Crossref
Crossref
Christopher B. Driscoll, Matthew R. Schuelke, Timothy Kottke, Jill M. Thompson, Phonphimon Wongthida, Jason M. Tonne, Amanda L. Huff, Amber Miller, Kevin G. Shim, Amy Molan, Cynthia Wetmore, Peter Selby, Adel Samson, Kevin Harrington, Hardev Pandha, Alan Melcher, Jose S. Pulido, Reuben Harris, Laura Evgin & Richard G. Vile. (2020) APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nature Communications 11:1.
Crossref
Crossref
Jacob J. Adashek, Pedro Nazareth Aguiar Junior, Natalie Galanina & Razelle Kurzrock. (2019) Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Theodoulakis Christofi & Apostolos Zaravinos. (2019) RNA editing in the forefront of epitranscriptomics and human health. Journal of Translational Medicine 17:1.
Crossref
Crossref
Zhishan Chen, Wanqing Wen, Jiandong Bao, Krystle L. Kuhs, Qiuyin Cai, Jirong Long, Xiao-ou Shu, Wei Zheng & Xingyi Guo. (2019) Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types. BMC Medical Genomics 12:1.
Crossref
Crossref
Abby M. Green & Matthew D. Weitzman. (2019) The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities. DNA Repair 83, pages 102700.
Crossref
Crossref
Daniel L. Faden, Fei Ding, Yan Lin, Shuyan Zhai, Fengshen Kuo, Timothy A. Chan, Luc G. Morris & Robert L. Ferris. (2019) APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. Oral Oncology 96, pages 140-147.
Crossref
Crossref
Hao Chen, Wei Chong, Changcai Teng, Yueliang Yao, Xin Wang & Xue Li. (2019) The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer. Cancer Science 110:8, pages 2348-2356.
Crossref
Crossref
C. Luchini, F. Bibeau, M.J.L. Ligtenberg, N. Singh, A. Nottegar, T. Bosse, R. Miller, N. Riaz, J.-Y. Douillard, F. Andre & A. Scarpa. (2019) ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Annals of Oncology 30:8, pages 1232-1243.
Crossref
Crossref
Laura Evgin, Amanda L. Huff, Timothy Kottke, Jill Thompson, Amy M. Molan, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Phonphimon Wongthida, Elizabeth J. Ilett, Karen Kaluza Smith, Reuben S. Harris, Matt Coffey, Jose S. Pulido, Hardev Pandha, Peter J. Selby, Kevin J. Harrington, Alan Melcher & Richard G. Vile. (2019) Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. Cancer Immunology Research 7:5, pages 828-840.
Crossref
Crossref
Yue Song, Zhaoming Li, Weili Xue & Mingzhi Zhang. (2019) Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy 11:6, pages 515-529.
Crossref
Crossref
Ming Yi, Dechao Jiao, Hanxiao Xu, Qian Liu, Weiheng Zhao, Xinwei Han & Kongming Wu. (2018) Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Molecular Cancer 17:1.
Crossref
Crossref
Katherine M. Bever & Dung T. Le. (2018) DNA repair defects and implications for immunotherapy. Journal of Clinical
Investigation 128:10, pages 4236-4242.
Crossref
Crossref
Natalie Galanina, Aaron M. Goodman, Philip R. Cohen, Garrett M. Frampton & Razelle Kurzrock. (2018) Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunology Research 6:10, pages 1129-1135.
Crossref
Crossref
Aaron M. Goodman, David Piccioni, Shumei Kato, Amélie Boichard, Huan-You Wang, Garrett Frampton, Scott M. Lippman, Caitlin Connelly, David Fabrizio, Vincent Miller, Jason K. Sicklick & Razelle Kurzrock. (2018)
Prevalence of
PDL1
Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
. JAMA Oncology 4:9, pages 1237.
Crossref
Crossref
Jianlong Gao, Hani Choudhry & Wei Cao. (2018)
Apolipoprotein B
mRNA
editing enzyme catalytic polypeptide‐like family genes activation and regulation during tumorigenesis
. Cancer Science 109:8, pages 2375-2382.
Crossref
Crossref
Panagiotis J. Vlachostergios & Bishoy M. Faltas. (2018) Treatment resistance in urothelial carcinoma: an evolutionary perspective. Nature Reviews Clinical Oncology 15:8, pages 495-509.
Crossref
Crossref
Shixiang Wang, Mingming Jia, Zaoke He & Xue-Song Liu. (2018) APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene 37:29, pages 3924-3936.
Crossref
Crossref
S. Venkatesan, R. Rosenthal, N. Kanu, N. McGranahan, J. Bartek, S.A. Quezada, J. Hare, R.S. Harris & C. Swanton. (2018) Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Annals of Oncology 29:3, pages 563-572.
Crossref
Crossref
Maria Gonzalez-Cao, Niki Karachaliou, Mariacarmela Santarpia, Santiago Viteri, Andreas Meyerhans & Rafael Rosell. (2018) Activation of viral defense signaling in cancer. Therapeutic Advances in Medical Oncology 10, pages 175883591879310.
Crossref
Crossref
Tomoaki Sasaki, Natalia Issaeva, Wendell G. Yarbrough & Karen S. Anderson. 2018. Molecular Determinants of Head and Neck Cancer. Molecular Determinants of Head and Neck Cancer
275
292
.
Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip P. Patel, Garrett M. Frampton, Vincent Miller, Philip J. Stephens, Gregory A. Daniels & Razelle Kurzrock. (2017) Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Molecular Cancer Therapeutics 16:11, pages 2598-2608.
Crossref
Crossref
Yulian Khagi, Aaron M. Goodman, Gregory A. Daniels, Sandip P. Patel, Assuntina G. Sacco, James M. Randall, Lyudmila A. Bazhenova & Razelle Kurzrock. (2017) Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy. Clinical Cancer Research 23:19, pages 5729-5736.
Crossref
Crossref